Biomarin raises Voxzogo sales expectations again

US-based Biomarin has recently launched its dwarfism drug Voxzogo, and the company is now increasing its sales expectations for the drug for the second time.
Photo: Anders Rye Skjoldjensen
Photo: Anders Rye Skjoldjensen
by christian bundgaard, translated by daniel pedersen

When Biomarin released its full-year report for 2021, the company also increased its sales expectations for Voxzogo, a treatment for achondroplasia, also known as dwarfism.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading